Elimination of ephedrines in urine following multiple dosing: The consequences for athletes, in relation to doping control

British Journal of Clinical Pharmacology

Volumn 57, Issue 1, 2004, Pages 62-67

  Chester, Neil ^a   Mottram, David R ^a   Reilly, Thomas ^a   Powell, Mark ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b Quay Pharmaceuticals Limited   (United Kingdom)

Author keywords

Doping control; Elimination; Ephedrines; Phenylpropanolamine; Pseudoephedrine

Indexed keywords

DECONGESTIVE AGENT; EPHEDRINE; NON PRESCRIPTION DRUG; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE;

ADULT; ARTICLE; ATHLETE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CONTINENCE; CONTROLLED STUDY; DOPING; DRUG ELIMINATION; DRUG URINE LEVEL; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PERMISSIBLE DOSE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; URINALYSIS; URINE; VOLUNTEER;

ADULT; BLOOD PRESSURE; DOPING IN SPORTS; DOUBLE-BLIND METHOD; DRUGS, NON-PRESCRIPTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPHEDRINE; HEART RATE; HUMANS; MALE; NASAL DECONGESTANTS; PHENYLPROPANOLAMINE; SUBSTANCE ABUSE DETECTION; SYMPATHOMIMETICS;

EID: 0347319051     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01948.x     Document Type: Article

References (24)

1. Olympic Movement Anti-Doping Code (2001) Appendix A prohibited classes of substances and prohibited methods 2001-02 1 September 2001:http://multimedia. olympic.org/pdf/en_report_22.pdf (Accessed 15/05/2002).
2. Olympic Movement Anti-Doping Code (2000) Appendix A prohibited classes of substances and prohibited methods 28 May 2000: http://multimedia.olympic.org/ pdf/en_report_21.pdf (Accessed 15/02/2002).
3. Shargel L, Silverman HI, Cohen P, Brisson J, Dennis S. Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. Biopharm Drug Dispos 1989; 11: 569-83.
4. Scherzinger SS, Dowse R, Kanfer I. Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. J Clin Pharmacol 1990; 30: 372-7.
5. Findlay JWA, Warren JT, Hill JA, Welch RM. Stereospecific radioimmunoassays for pseudoephedrine in human plasma and their application to bioequivalency studies. J Pharm Sci 1981; 70: 624-31.
6. Chester N. The use of sympathomimetic amines in sport and exercise. Unpublished PhD Thesis Liverpool John Moores University 2000.
7. Zimmerman CL. The effect of urinary pH modification on the disposition of phenylpropanolamine. Pharm Res 1988; 5: 120-2.
8. Heimlich KR, MacDonnell DR, Flanagan TL, O'Brien PD. Evaluation of a sustained release form of phenylpropanolamine hydrochloride by urinary excretion studies. J Pharm Sci 1961; 50: 232-7.
9. Dowse R, Haigh JM, Kanfer I. Pharmacokinetics of phenylpropanolamine in humans after a single-dose study. Int J Pharm 1987; 39: 141-8.
10. Zimmerman CL, O'Connell MB, Soria I. The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine. Pharm Res 1990; 7: 96-102.
11. O'Connell MB, Pentel PR, Zimmerman CL. Individual variability in the blood pressure response to intravenous phenylpropanolamine: a pharmacokinetic and pharmacodynamic investigation. Clin Pharmacol Ther 1989; 45: 252-9.
12. Brater DC, Kaojarern S, Benet LZ, Lin ET, Lockwood T, Morris RC, McSherry EJ, Melmon KL. Renal excretion of pseudoephedrine. Clin Pharmacol Ther 1980; 28: 690-4.
13. Bye C, Hill HM, Hughes DTD, Peck AW. A comparison of plasma levels of L (+) Pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. Europ J Clin Pharmacol 1975; 8: 47-53.
14. Lucarotti RL, Colaizzi JL, Barry H, Poust RI. Enhanced pseudoephedrine absorption by concurrent administration of aluminum hydroxide gel in humans. J Pharm Sci 1972; 61: 903-5.
15. Lo LY, Land G, Bye A. Sensitive assay for pseudoephedrine and its metabolite, norpseudoephedrine in plasma and urine using gas-liquid chromatography with electron-capture detection. J Chromatgr 1981; 222: 297-302.
16. Delbeke FT, Debackere M. The influence of diuretics in the excretion and metabolism of doping agents. VI. Pseudoephedrine. Biopharm Drug Dispos 1991; 12: 37-48.
17. Baaske DM, Lai CM, Klein L, Look ZM, Yacobi A. Comparison of GLC and high-pressure liquid chromatographic methods for analysis of urinary pseudoephedrine. J Pharm Sci 1979; 68: 1472.
18. Lai CM, Stoll RG, Look ZM, Yacobi A. Urinary excretion of chlorpheniramine and pseudoephedrine in humans. J Pharm Sci 1979; 68: 1243-6.
19. Benezra SA, McRae JW. Pseudoephedrine hydrochloride. In: Analytical Profiles of Drug Substances (Ed. by by Florey, K New York). Academic Press 1979, 489-507.
20. Wilkinson GR, Beckett AH. Absorption, metabolism and excretion of the ephedrines in man I. The influence of urinary pH and urine Volume output. J Pharmacol Exp Therapeutics, 1968; 162: 139-47.
21. Lefebvre RA, Surmont F, Bouckaert J, Moerman E. Urinary excretion of ephedrine after nasal application in healthy volunteers. J Pharm Pharmacol 1992; 44: 672-5.
22. Kuitunen T, Karkkainen S, Ylitalo P. Comparison of the acute physical and mental effects of ephedrine, fenfluramine, phentermine and prolitane. Meth Find Exptl Clin Pharmacol 1984; 6: 265-70.
23. Bye C, Dewsbury D, Peck AW. Effects on the human central nervous system of two isomers of ephedrine and triprolidine and their interaction. Br J Clin Pharmac 1974; 1: 71-8.
24. Bright TP, Sandage BW, Fletcher HP. Selected cardiac and metabolic responses to pseudoephedrine with exercise. J Clin Pharmacol 1981; 21: 488-92.